Patrick Campbell

The American College of Physicians has released guidelines, which include 4 new recommendations, for the treatment of age-related low testosterone in men.

A new study from George Mason University is offering additional insight into the impact of e-cigarette and combustible cigarette use on a person's risk of stroke.

A study from investigators at UCLA has identified a biomarker investigators suggest can help identify stable heart failure patients at an increased risk of death within the next 3 years.

Novo Nordisk announced the US FDA's approval of insulin aspart injection 100 u/mL (Fiasp) for glycemic control in children in a press release on Monday morning.

A recent study examining 140 Australians found alcohol abstinence reduced the recurrence and burden of atrial fibrillation in regular drinkers between the ages of 18 and 85 years old.

Increased levels of pyrethroid insecticide exposure was linked to increased in all-cause mortality, as well as increases in mortality from cancer and cardiovascular disease in a recent study from the University of Iowa.

The US Food and Drug Administration has announced a comprehensive ban on flavored, pod-based e-cigarette cartridges earlier this week.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.

TAVR has revolutionized treatment for aortic stenosis but we are still learning more about how to best manage antithrombotic strategy following this procedure.

A recent study from McMaster University has revealed NT-proBNP levels could serve as a predictor of cardiac injury after noncardiac procedures.

A decade of fine-tuning proven therapies and embracing advancing clinical technology has put ophthalmology in a rare space.

The US FDA has announced the approval of 2 applications for apixaban—marking the first generic approval of a direct oral anticoagulant.

Lumateperone (Caplyta), a novel therapy, has received approval from the US FDA for the treatment of schizophrenia in adults.

A study of TAVR and SAVR admissions over a 4-year period revealed 30-day mortality rates may be misrepresenting outcomes at 1 year.

A new study from Queen Mary University of London is revealing more about the potential impact of cannabis on cardiovascular health and function.

A new study published in Hypertension has found long work hours increased a person's risk for sustained and masked hypertension.

Results of the VESUVIUS trial are adding fuel to the fire in the debate over the impact of electronic cigarettes in former tobacco users.

A recent analysis from Tulane University has found a healthy sleep pattern could at least partially offset risk of stroke or cardiovascular disease in patients with a high genetic risk.

A new study from Brigham and Women's Hospital found a home hospital model of care reduced cost while maintaining standards of care compared to typical in-hospital care.

In March 2020, the therapy has the potential to become the first approved for the rare autoimmune disorder.

A research letter published in JAMA Network Open is painting a clearer picture of how the introduction of a biosimilar impacts trends in pricing, cost, and discounts related to the originator biologic.

The FDA has granted marketing authorization for the GSP Neonatal Creatine Kinase-MM to aid physicians in screening newborns for Duchenne Muscular Dystrophy.

A meta-analysis of more than 1 million patients and 2 dozen studies has revealed patients over 60 with hypothyroidism were at a 26% greater chance of all-cause mortality.

An analysis of the Dongfeng-Tongi cohort has revealed sleeping more than 9 hours per night or taking midday naps lasting longer than 90 minutes was associated with an increase in risk of total stroke.

A study from SUNY University at Buffalo has found adherence to a Western diet could contribute to the development of late age-related macular degeneration.

A new study of more than 60,000 individuals over the course of a decade suggests non-Hispanic blacks were less likely to use and see benefits from low-dose aspirin in the same way as non-Hispanic whites.

Results of a phase 3 study presented during the late-breaking sessions at ASH 2019 has found CC-486 provided patients with significant and meaningful improvements in overall survival (OS) and relapse-free survival.

Results of a phase 3 study presented at ASH 2019 are suggesting blinatumomab was more effective than chemotherapy as a post-reinduction therapy in high and intermediate risk first relapse of b-acute lymphoblastic leukemia.

Results of an interim analysis of a phase 2 trial are suggesting enasidenib plus azacitidine may be more effective than azacitidine monotherapy alone.

An updated meta-analysis from ASH 2019 is detailing the apparent risk of atrial fibrillation and major bleeding associated with ibrutinib use in patients with hematologic malignancies.